Granite Investment Partners LLC lessened its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 13.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 31,311 shares of the biotechnology company's stock after selling 4,861 shares during the period. Granite Investment Partners LLC owned about 0.06% of Repligen worth $4,507,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Groupama Asset Managment raised its position in shares of Repligen by 12,321.0% in the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock worth $58,142,000 after acquiring an additional 400,680 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Repligen during the fourth quarter valued at about $52,492,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of Repligen by 79.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock valued at $65,395,000 after buying an additional 203,011 shares in the last quarter. Alliancebernstein L.P. raised its stake in shares of Repligen by 23.4% during the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock worth $145,508,000 after acquiring an additional 191,439 shares in the last quarter. Finally, Norges Bank purchased a new stake in Repligen during the fourth quarter valued at approximately $24,034,000. 97.64% of the stock is currently owned by institutional investors.
Insider Transactions at Repligen
In related news, Director Margaret Pax acquired 250 shares of the business's stock in a transaction on Monday, March 17th. The shares were bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.20% of the company's stock.
Repligen Stock Down 1.6 %
RGEN traded down $2.10 during trading hours on Friday, hitting $130.00. 753,355 shares of the company's stock were exchanged, compared to its average volume of 707,222. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12-month low of $102.97 and a 12-month high of $182.52. The firm has a market cap of $7.30 billion, a P/E ratio of -254.90, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The firm has a 50 day moving average of $140.76 and a 200 day moving average of $145.82.
Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on RGEN shares. Royal Bank of Canada boosted their price target on Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research note on Friday, February 21st. HC Wainwright reissued a "buy" rating and set a $180.00 price target on shares of Repligen in a report on Friday, February 21st. StockNews.com downgraded shares of Repligen from a "hold" rating to a "sell" rating in a research report on Thursday. Evercore ISI started coverage on Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price target for the company. Finally, JPMorgan Chase & Co. raised their price objective on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $176.82.
View Our Latest Analysis on Repligen
Repligen Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Stories
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
